Intrinsiqq
Replimune Group Inc. logo

Replimune Group Inc. Financials

REPL

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 9 available years
Income Statement
MAR 2026
MAR 2025
MAR 2024
MAR 2023
MAR 2022
General & Administrative$99$72$60$51$39
Research & Development$221$189$175$127$80
Total Operating Expenses$320$262$235$177$118
Operating Income-$320-$262-$235-$177-$118
Non-Operating
Net Interest Expense$7$15$19$8$0
Other Non-Operating Income (Expense)-$1-$1$1-$5-$0
EBT (Earnings Before Tax)-$314-$247-$215-$174-$118
Income Tax Expense-$1$0$0$0$0
Earnings from Continuing Ops-$314-$247-$215-$174-$118
Net Income
Net Income-$314-$247-$216-$174-$118
EPS (Basic)-$3.38-$3.07-$3.24-$2.99-$2.26
EPS (Diluted)-$3.38-$3.07-$3.24-$2.99-$2.26
Weighted Avg Shares (Basic)92.8M80.6M66.6M58.2M52.2M
Weighted Avg Shares (Diluted)92.8M80.6M66.6M58.2M52.2M
Shares Outstanding92.8M80.6M66.6M58.2M52.2M

Replimune Group (REPL) financials: revenue, profit and margins

Replimune Group (REPL) generated about n/a in revenue and -$271 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Replimune Group profitable?+

Replimune Group reported about -$271 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 23 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 10 Nov 2026. How this is calculated.

Fiscal year ends Mar.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with REPL

CompareIntrinsic value
ARTVArtiva Biotherapeutics Inc.
$3.78-1.31%10
SRZNSurrozen, Inc.
$28.46-7.21%10
CHRSCoherus Biosciences Inc.
$0.37-4.44%10
DNAGinkgo Bioworks Holdings Inc.
$7.46-9.02%15
IMAImageneBio, Inc.
$3.92-1.51%10
EDITEditas Medicine Inc.
$1.64-4.09%40
CMPXCompass Therapeutics Inc.
$0.69+1.40%10
IBRXImmunityBio, Inc.
$6.02-8.37%30

Held by ETFs

REPL is in 26 US ETFs. The largest of them, with REPL's weight in each:

Spot a number that looks wrong? Check it in REPL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing REPL

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.